Biodel Inc.
100 Saw Mill Road
Danbury,
CT 06810
United States - Map
Phone: 203-796-5000
Fax: 203-796-5001
Web Site: http://www.biodel.com
| Biodel, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis in the United States. The company develops its product candidates by utilizing its proprietary VIAdel technology. It has two insulin product candidates in clinical trials for the treatment of diabetes, including VIAject and VIAtab. VIAject is an injectable formulation of recombinant human insulin, which is in pivotal Phase III clinical trials in patients with Type 1 and Type 2 diabetes. VIAtab is a sublingual tablet formulation of insulin, which is in Phase I clinical trial in patients with Type 1 diabetes. Biodel also has two preclinical product candidates for the treatment of osteoporosis comprising VIAmass, a sublingual formulation of parathyroid hormone 1-34; and VIAcal, a sublingual formulation of salmon calcitonin. The company was founded in 2003 and is based in Danbury, Connecticut. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Solomon S. Steiner Ph. D., 71
Founder, Chairman, Chief Exec. Officer and Pres |
$
358.00K | N/A | Mr. Erik Steiner , 43
Co-Founder and VP of Operations |
$
216.00K | N/A | Mr. Gerard J. Michel MS, MBA, 45
Chief Financial Officer, Chief Accounting Officer, VP of Corp. Devel. and Treasurer |
$
299.00K | N/A | Dr. Alan Krasnser M.D., 46
Chief Medical Officer |
N/A
| N/A | Paul S. Bavier ,
Sec. and Gen. Counsel |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.01% Nasdaq 
0.22%
Profile
